Chinese state media is championing Sinovac’s new vaccine, focussing largely on the positives while minimizing the fact that the public release of its efficacy data has raised international eyebrows.
Various regulators worldwide said they would take a close look at the data for Sinovac Biotech’s CoronaVac product, which the company’s Brazilian partner, the Butantan Institute, said on Tuesday had a roughly 50% general efficacy rate – well below the 78% reported earlier.
But there was little mention in Chinese media on Thursday of the questions raised by the results.
“Sinovac releases vaccine data in Brazil: 100% effective in preventing severe cases, could reduce hospitalization by 80%,” natio
•
Jan 15, 2021